CNP (C-Type Natriuretic Peptide)

Overview

C-type natriuretic peptide (CNP) is the third member of the natriuretic peptide family, alongside atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP). While ANP and BNP function primarily as circulating cardiac hormones regulating blood pressure and fluid balance, CNP operates predominantly as a local paracrine and autocrine factor. It was identified in 1990 by Sudoh and colleagues from porcine brain tissue, initially suggesting a neural function, but subsequent research revealed CNP's most critical roles are in endochondral bone growth, vascular biology, and reproduction.

CNP exists in two forms: CNP-53 (the predominant tissue form) and CNP-22 (the mature processed form). Unlike ANP and BNP, CNP has minimal natriuretic (sodium-excreting) and diuretic activity. Instead, it acts locally in tissues where it is produced — particularly the growth plate cartilage of developing bones, vascular endothelium, and reproductive organs.

The most significant translational impact of CNP biology has been the development of vosoritide (brand name Voxzogo), a modified CNP analog approved in 2021 for the treatment of achondroplasia in children. Vosoritide works by counteracting the overactive FGFR3 signaling that inhibits bone growth in achondroplasia, providing the first medication that directly addresses the underlying growth plate dysfunction. This approval established CNP as one of the few natriuretic peptides to be successfully developed into a targeted therapeutic.

Amino Acid Sequence

CNP exists in two processed forms derived from a 126-amino acid precursor (preproCNP):

CNP-22: GLSKGCFGLKLDRIGSMSGLGC (22 amino acids) CNP-53: N-terminal extended form with 31 additional residues

• Molecular weight: CNP-22: ~2,197 g/mol; CNP-53: ~5,800 g/mol
• Gene: NPPC (chromosome 2q37.1)
• Receptor: Natriuretic peptide receptor B (NPR-B/GC-B)
• CAS Number: 127869-51-6 (CNP-22)

Structural features:

• 17-amino acid disulfide ring — formed by Cys6-Cys22 disulfide bond; conserved across the natriuretic peptide family
• No C-terminal tail — unlike ANP and BNP, CNP lacks amino acids extending beyond the disulfide ring, which accounts for its different receptor selectivity
• NPR-B selectivity — CNP binds NPR-B (guanylyl cyclase B) with high affinity but has very low affinity for NPR-A (the receptor for ANP and BNP), explaining its distinct biological profile

Mechanism of Action

NPR-B / cGMP Signaling

CNP binds natriuretic peptide receptor B (NPR-B), a transmembrane guanylyl cyclase:

1. CNP binds the extracellular domain of NPR-B
2. Receptor dimerization activates the intracellular guanylyl cyclase domain
3. cGMP is produced as a second messenger
4. cGMP activates cGMP-dependent protein kinases (PKG/cGKII)
5. PKG phosphorylates downstream targets specific to cell type

CNP is also cleared by natriuretic peptide receptor C (NPR-C), a clearance receptor shared with ANP and BNP, and degraded by neprilysin (neutral endopeptidase).

Endochondral Bone Growth

CNP's most physiologically critical role is promoting longitudinal bone growth at the growth plate:

• CNP/NPR-B signaling in growth plate chondrocytes stimulates proliferation and hypertrophy
• PKG (cGKII) phosphorylates and inhibits RAF-1, blocking the MAPK/ERK cascade downstream of FGFR3
• In achondroplasia, a gain-of-function mutation in FGFR3 causes constitutive activation of MAPK signaling, suppressing chondrocyte proliferation and bone growth
• CNP counteracts this by inhibiting the FGFR3-MAPK pathway at the RAF-1 level
• Loss-of-function mutations in NPPC (CNP gene) or NPR2 (NPR-B gene) in humans cause short stature
• Gain-of-function mutations in NPR2 cause tall stature (overgrowth)

Vascular Effects

• CNP is the primary natriuretic peptide produced by vascular endothelial cells
• Acts on vascular smooth muscle NPR-B to produce cGMP-mediated vasodilation
• Anti-proliferative effect on smooth muscle cells — inhibits neointimal hyperplasia
• Anti-inflammatory effects on endothelium
• Functions as a local paracrine vasodilator rather than a circulating hormone

Reproductive Biology

• Required for female fertility: CNP/NPR-B signaling maintains oocyte meiotic arrest in follicles
• CNP maintains high cGMP levels in cumulus cells, which transfers to the oocyte via gap junctions
• LH surge decreases CNP, reducing cGMP and permitting meiotic resumption

Research Summary

Pharmacokinetics

• Half-life: CNP-22: approximately 2-3 minutes in circulation (rapidly cleared by NPR-C and neprilysin); CNP-53: slightly longer
• Circulating levels: Very low (2-5 pg/mL); CNP functions primarily as a paracrine factor, not a circulating hormone
• Metabolism: Degraded by neprilysin (NEP) and cleared by NPR-C (clearance receptor)
• Tissue expression: Endothelium, growth plate chondrocytes, brain, reproductive organs, heart

Clinical Application: Vosoritide

Vosoritide (Voxzogo) is a 39-amino acid CNP analog designed to overcome the rapid degradation of native CNP:

• Structure: Modified CNP-39 with extensions that resist neprilysin cleavage
• Indication: Achondroplasia in children aged 5 years and older with open growth plates
• Mechanism: Counteracts the excessive FGFR3/MAPK signaling that inhibits growth plate chondrocyte proliferation
• Efficacy: Increases annualized growth velocity by ~1.5 cm/year compared to untreated children
• Administration: Daily subcutaneous injection
• Half-life: ~30 minutes (vs. 2-3 minutes for native CNP)

Common Discussion Topics

1. CNP vs. ANP/BNP — While ANP and BNP are circulating cardiac hormones, CNP is fundamentally different: a paracrine factor with minimal natriuretic activity and primary roles in bone and vasculature rather than fluid balance.

2. Achondroplasia breakthrough — The development of vosoritide from CNP biology represents a textbook example of translating basic peptide biology into targeted therapy. Understanding CNP's mechanism at the growth plate directly informed drug design.

3. Growth plate biology — CNP is essential for the complex signaling that regulates bone lengthening. The balance between CNP (pro-growth) and FGFR3 (growth-limiting) determines growth plate activity, and perturbations in either direction cause clinical skeletal conditions.

4. Fertility connection — CNP's role in maintaining oocyte meiotic arrest adds an unexpected reproductive dimension to natriuretic peptide biology, distinct from any cardiovascular function.

5. Short half-life challenge — Native CNP's 2-3 minute half-life made therapeutic development challenging and required the structural modifications incorporated into vosoritide.

Related Compounds

• ANP — atrial natriuretic peptide; circulating cardiac hormone with natriuretic activity (NPR-A receptor)
• BNP — B-type natriuretic peptide; cardiac biomarker and heart failure therapeutic
• Vosoritide — therapeutic CNP analog approved for achondroplasia
• Nesiritide — recombinant BNP used in heart failure (different receptor: NPR-A)